TY - JOUR
T1 - LOGGIC Core BioClinical Data Bank
T2 - Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients
AU - Hardin, Emily C
AU - Schmid, Simone
AU - Sommerkamp, Alexander
AU - Bodden, Carina
AU - Heipertz, Anna-Elisa
AU - Sievers, Philipp
AU - Wittmann, Andrea
AU - Milde, Till
AU - Pfister, Stefan M
AU - von Deimling, Andreas
AU - Horn, Svea
AU - Herz, Nina A
AU - Simon, Michèle
AU - Perera, Ashwyn A
AU - Azizi, Amedeo
AU - Cruz, Ofelia
AU - Curry, Sarah
AU - Van Damme, An
AU - Garami, Miklos
AU - Hargrave, Darren
AU - Kattamis, Antonis
AU - Kotnik, Barbara Faganel
AU - Lähteenmäki, Päivi
AU - Scheinemann, Katrin
AU - Schouten-van Meeteren, Antoinette Y N
AU - Sehested, Astrid
AU - Viscardi, Elisabetta
AU - Wormdal, Ole Mikal
AU - Zapotocky, Michal
AU - Ziegler, David S
AU - Koch, Arend
AU - Driever, Pablo Hernáiz
AU - Witt, Olaf
AU - Capper, David
AU - Sahm, Felix
AU - Jones, David T W
AU - van Tilburg, Cornelis M
N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2023/11/1
Y1 - 2023/11/1
N2 - BACKGROUND: The international, multicenter registry LOGGIC Core BioClinical Data Bank aims to enhance the understanding of tumor biology in pediatric low-grade glioma (pLGG) and provide clinical and molecular data to support treatment decisions and interventional trial participation. Hence, the question arises whether implementation of RNA sequencing (RNA-Seq) using fresh frozen (FrFr) tumor tissue in addition to gene panel and DNA methylation analysis improves diagnostic accuracy and provides additional clinical benefit.METHODS: Analysis of patients aged 0 to 21 years, enrolled in Germany between April 2019 and February 2021, and for whom FrFr tissue was available. Central reference histopathology, immunohistochemistry, 850k DNA methylation analysis, gene panel sequencing, and RNA-Seq were performed.RESULTS: FrFr tissue was available in 178/379 enrolled cases. RNA-Seq was performed on 125 of these samples. We confirmed KIAA1549::BRAF-fusion (n = 71), BRAF V600E-mutation (n = 12), and alterations in FGFR1 (n = 14) as the most frequent alterations, among other common molecular drivers (n = 12). N = 16 cases (13%) presented rare gene fusions (eg, TPM3::NTRK1, EWSR1::VGLL1, SH3PXD2A::HTRA1, PDGFB::LRP1, GOPC::ROS1). In n = 27 cases (22%), RNA-Seq detected a driver alteration not otherwise identified (22/27 actionable). The rate of driver alteration detection was hereby increased from 75% to 97%. Furthermore, FGFR1 internal tandem duplications (n = 6) were only detected by RNA-Seq using current bioinformatics pipelines, leading to a change in analysis protocols.CONCLUSIONS: The addition of RNA-Seq to current diagnostic methods improves diagnostic accuracy, making precision oncology treatments (MEKi/RAFi/ERKi/NTRKi/FGFRi/ROSi) more accessible. We propose to include RNA-Seq as part of routine diagnostics for all pLGG patients, especially when no common pLGG alteration was identified.
AB - BACKGROUND: The international, multicenter registry LOGGIC Core BioClinical Data Bank aims to enhance the understanding of tumor biology in pediatric low-grade glioma (pLGG) and provide clinical and molecular data to support treatment decisions and interventional trial participation. Hence, the question arises whether implementation of RNA sequencing (RNA-Seq) using fresh frozen (FrFr) tumor tissue in addition to gene panel and DNA methylation analysis improves diagnostic accuracy and provides additional clinical benefit.METHODS: Analysis of patients aged 0 to 21 years, enrolled in Germany between April 2019 and February 2021, and for whom FrFr tissue was available. Central reference histopathology, immunohistochemistry, 850k DNA methylation analysis, gene panel sequencing, and RNA-Seq were performed.RESULTS: FrFr tissue was available in 178/379 enrolled cases. RNA-Seq was performed on 125 of these samples. We confirmed KIAA1549::BRAF-fusion (n = 71), BRAF V600E-mutation (n = 12), and alterations in FGFR1 (n = 14) as the most frequent alterations, among other common molecular drivers (n = 12). N = 16 cases (13%) presented rare gene fusions (eg, TPM3::NTRK1, EWSR1::VGLL1, SH3PXD2A::HTRA1, PDGFB::LRP1, GOPC::ROS1). In n = 27 cases (22%), RNA-Seq detected a driver alteration not otherwise identified (22/27 actionable). The rate of driver alteration detection was hereby increased from 75% to 97%. Furthermore, FGFR1 internal tandem duplications (n = 6) were only detected by RNA-Seq using current bioinformatics pipelines, leading to a change in analysis protocols.CONCLUSIONS: The addition of RNA-Seq to current diagnostic methods improves diagnostic accuracy, making precision oncology treatments (MEKi/RAFi/ERKi/NTRKi/FGFRi/ROSi) more accessible. We propose to include RNA-Seq as part of routine diagnostics for all pLGG patients, especially when no common pLGG alteration was identified.
KW - Child
KW - DNA-Binding Proteins/genetics
KW - Glioma/pathology
KW - Humans
KW - Pathology, Molecular
KW - Precision Medicine
KW - Protein-Tyrosine Kinases
KW - Proto-Oncogene Proteins B-raf/genetics
KW - Proto-Oncogene Proteins/genetics
KW - RNA-Seq
KW - Transcription Factors/genetics
KW - RNA sequencing
KW - actionable drivers
KW - pLGG
KW - rare gene fusions
KW - molecular profiling
UR - http://www.scopus.com/inward/record.url?scp=85176495511&partnerID=8YFLogxK
U2 - 10.1093/neuonc/noad078
DO - 10.1093/neuonc/noad078
M3 - Journal article
C2 - 37075810
SN - 1522-8517
VL - 25
SP - 2087
EP - 2097
JO - Neuro-Oncology
JF - Neuro-Oncology
IS - 11
ER -